Canadian experts warn Ebola outbreak in Congo is 'race against time' with no approved vaccine

When Jason Kindrachuk first heard about the Ebola outbreak spreading through the Democratic Republic of Congo more than a week ago, he allowed himself a measure of hope. He had worked on the ground before. He knew the caliber of the local health workers. He understood the systems, or what remained of them. But as the numbers climbed—past 500 cases, then past 1,000—his optimism eroded.

The outbreak is moving faster than the response can follow. More than 1,000 suspected infections have been documented, concentrated in the northeastern provinces of Ituri and North Kivu, with hundreds dead and seven cases confirmed across the border in Uganda. Scientists believe the true count is substantially higher, since the virus was likely circulating for weeks before anyone outside the region recognized what was happening. What makes this outbreak particularly grim is that it's caused by the Bundibugyo strain of Ebola—a relatively uncommon variant for which no approved vaccine exists and no proven treatment is available. "It's really a race against time," Kindrachuk, an associate professor of microbiology at the University of Manitoba, told CBC News. "The faster we can identify suspected cases, the faster we can try to get things contained. But the unfortunate reality is that we're not looking at a few weeks of this."

The World Health Organization's director-general, Dr. Tedros Adhanom Ghebreyesus, made much the same assessment during a virtual briefing with African officials. The delay in detecting the outbreak means response teams are now "playing catch-up with a very fast-moving epidemic," he said, one that he expects will "get worse before it gets better." At the moment, he acknowledged, "the epidemic is outpacing us."

The obstacles facing health workers are stacked and interconnected. There is no vaccine to prevent new infections. There is active, intensifying violence in the affected provinces—fires have been set at health facilities, and dozens of Ebola patients have fled treatment sites. There is deep distrust of outside authorities and international responders. And there is the sheer geography and infrastructure of Congo itself: vast territories without paved roads, remote regions that can take days to reach from the capital, and a public health system that was already fragile before the outbreak and has grown more so as international support has diminished in recent years.

Kindrachuk worked in Liberia during the 2014 West African Ebola epidemic, which involved the Zaire strain and killed tens of thousands over more than two years. That outbreak, too, had no vaccine at the time. But the vaccine that was eventually developed and approved was built specifically for Zaire. The current outbreak is different. Experimental vaccines are being scaled up—including one developed at Oxford University that carries genetic code from the Bundibugyo virus—but these efforts will take time. Darryl Falzarano, a Canadian vaccine researcher who has worked on antiviral strategies for Ebola, expressed frustration that approved vaccines don't exist for non-Zaire strains despite the underlying science being well understood. "It's not a technological reason," he said. "It's a societal, financial reason."

The conflict itself is a vector for disease. Nearly five million people live in Ituri province, the epicenter of the outbreak, amid ongoing violence. Health and humanitarian workers are fleeing the region, which the WHO says is "severely impeding efforts" to identify cases early enough to provide care. Dr. Rob Fowler, a critical care physician at Sunnybrook Hospital in Toronto who has worked on previous Ebola outbreaks in Congo, Guinea, Liberia, and Sierra Leone, emphasized that instability creates daily interruptions in contact tracing—the painstaking work of tracking down everyone who may have been exposed to the virus through bodily fluids. Without that work, the outbreak spreads invisibly.

The internal displacement of populations compounds the problem. As people flee zones of active infection or conflict, they become harder to track. Kindrachuk recalled a trip to remote Congo where a journey that should have taken hours required days of difficult travel. Multiply that logistical friction across millions of people, across a country the size of a continent, and the challenge becomes almost incomprehensible. Fowler also noted the physical toll on responders: working in full protective equipment in Africa's heat is exhausting. Without proper cooling systems built into the gear, teams cannot sustain patient care for extended periods. In the pre-vaccine era of 2014, there was enormous risk to frontline workers. "We're back into that," Kindrachuk said. "We need to ensure we can get folks tested diagnostically if there's any issue and get them out to care if they do show any symptoms."

What happens next depends on how quickly experimental vaccines can be deployed, how much violence can be contained or managed, and whether international support for Congo's health infrastructure can be restored and scaled. For now, the outbreak is winning the race.